AIBOTICS, INC.

Aibotics, Inc. focuses on the study of psychedelics for treating mental health issues and supports the creation of both natural and synthetic molecules for developing treatments. The company plans to use technology from its parent company, Ehave, Inc., to collect research and clinical data to further study the effects of psychedelics in mental health treatment. Through the acquisition of assets from Philon Labs, Aibotics intends to use Artificial Intelligence (AI) to transform ideas and solutions into products using advanced engineering and design techniques, aiming to enhance patient care and streamline medical processes. Aibotics, Inc. was incorporated in Nevada on January 21, 2000, as RM Investors, Inc. In March 2014, it acquired 100% of 20/20 Produce Sales, Inc., an Idaho corporation incorporated on December 22, 1994. On March 26, 2014, the company increased its authorized common stock to 100,000,000 shares, par value $0.001, and authorized 5,000,000 shares of preferred stock, par value $0.001. In December 2020, the company entered into agreements to purchase all outstanding stock of Aibotics, Inc. from Ehave, Inc. In May 2021, the company changed its name to Aibotics Therapies Inc. Its trading symbol is TPIA. The company has one subsidiary, Aibotics Therapies Inc., a Florida corporation.